PPARA and metabolic dysfunction-associated steatohepatitis: Fu et al. reported that lanifibranor, a pan-PPAR agonist, improved lipid metabolism, led to MASH resolution in 49% of patients, and produced ≥1-stage fibrosis improvement in 35% of cases [44].